Drugs / AZD8965
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06502379 | Aug 2024 → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07652658 | Jun 2026 → Sep 2028 expected | idiopathic pulmonary fibrosis | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8965 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652658 ↗ |
| Route | Oral | “administered orally” NCT06502379 ↗ |